ACTRN12623000332628尚未招募Unknown
A participant-blinded, randomized, 12-month, parallel-group study to compare the efficacy of two methods of inspiratory muscle training versus placebo therapy in the inspiratory muscle strength and pulmonary function in professional swimmers.
Agnieszka Lewinska0 个研究点目标入组 45 人开始时间: 2023年3月30日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Educational / counselling / training
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- All
入选标准
- •age 18 or over; written informed consent; active swimmer.
排除标准
- •contraindications for US imaging; present respiratory tract infection; interventions targeting respiratory muscle function in the past 12 months; a history of spontaneous pneumothorax; pulmonary hypertension; ruptured eardrum or any other condition of the ear.
研究者
相似试验
已完成
Unknown
Clinical study to evaluate the effectiveness and safety of eggshell powder to improve skin health (skin photo-aging and skin moisturizing)KCT0009068mariedm100
已完成
Unknown
Clinical study of rose petals extract to improve skin health (maintaining skin health and moisturizing skin from skin damage caused by ultraviolet rays)KCT0009064ovawells100
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in patients with essential hypertension - non aplicableHypertensionEUCTR2004-002252-33-ESovartis Farmacéutica S.A672
进行中（未招募）
不适用
A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in patients with essential hypertensioHypertensionEUCTR2004-002252-33-DEovartis Pharma Services AG672
进行中（未招募）
不适用
A 12-month, double-blind, double-dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2x160/4.5µg bid and 2x80/4.5 µg bid compared to Formoterol Turbuhaler 2x4.5µg bid and Placebo in patients with chronic obstructive pulmonary disease (COPD). - SThis is an application for a phase III study to be conducted in COPD patients.Classification code 10010952EUCTR2004-001168-28-ISAstraZeneca AB1,600